Fotis Asimakopoulos

Title(s)Professor In Residence, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Cambridge, Cambridge UKMD PhD01/1997Medicine, Hematology
    Hebrew University of Jerusalem, Jerusalem IsraelGolda Meir Fellow06/1999Hematology
    BWH, Harvard Medical School, Boston MAResidency06/2001Internal Medicine
    Memorial Sloan-Kettering Cancer Center, New York, NYFellowship06/2009Medical Oncology
    ABIM Board CertificationMedical Oncology
    Collapse Awards and Honors
    American Society for Clinical Investigation (ASCI)2023Elected Member

    Collapse Overview 
    Collapse Overview
    My lab has a core interest in modeling multiple myeloma, a tumor of antibody-producer plasma cells and the second most common blood cancer. Myeloma is not only a cancer type with growing incidence in the general population, but also a diagnosis prevalent in vulnerable groups, including Veterans exposed to chemicals such as Agent Orange, and Americans of African descent. Myeloma is arguably one of the most challenging cancers to model in the mouse. My group has employed several innovative approaches, firstly using lineage-specific, Avian Leukosis Virus-mediated in vivo gene transfer and more recently through conditional activation of N-Ras in the germinal center, in collaboration with Jing Zhang at UW-Madison, and Marta Chesi and Leif Bergsagel at Mayo. These approaches have generated myeloma models that recapitulate human high-risk multiple myeloma, a subset of proliferative, relapse-prone myeloma that remains poorly controlled by most current therapies and presents an area of unmet clinical need. My lab also has a major focus on the tumor microenvironment in myeloma, the stromal reaction, the extracellular matrix and the pathways through which matrix remodeling shapes the polarization of antigen-presenting cells in the tumor microenvironment. Stemming from the latter work, we are pursuing gene transfer approaches to generate novel cancer vaccines that harness this immune cell- matrix crosstalk.

    Collapse Research 
    Collapse Research Activities and Funding
    Tumor matrix remodeling in anti-myeloma immunity and immunotherapy
    NIH R01CA252937Jul 1, 2020 - Jun 30, 2025
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Emerging roles for tumor stroma in antigen presentation and anti-cancer immunity. Biochem Soc Trans. 2023 12 20; 51(6):2017-2028. Papadas A, Huang Y, Cicala A, Dou Y, Fields M, Gibbons A, Hong D, Lagal DJ, Quintana V, Rizo A, Zomalan B, Asimakopoulos F. PMID: 38031753; PMCID: PMC10754280.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    2. Heart-liver-kidney transplantation for AL amyloidosis using normothermic recovery and storage from a donor following circulatory death: Short-term outcome in a first-in-world experience. Am J Transplant. 2023 02; 23(2):291-293. Brubaker AL, Urey MA, Taj R, Parekh JR, Berumen J, Kearns M, Shah M, Khan A, Kono Y, Ajmera V, Barman P, Tran H, Adler ED, Silva Enciso J, Asimakopoulos F, Costello C, Bower R, Sanchez R, Pretorius V, Schnickel GT. PMID: 36804136.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer. J Transl Med. 2022 11 12; 20(1):527. Deichaite I, Sears TJ, Sutton L, Rebibo D, Morgan K, Nelson T, Rose B, Tamayo P, Ferrara N, Asimakopoulos F, Carter H. PMID: 36371231; PMCID: PMC9652804.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    4. Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment. Cell Rep. 2022 08 16; 40(7):111201. Papadas A, Deb G, Cicala A, Officer A, Hope C, Pagenkopf A, Flietner E, Morrow ZT, Emmerich P, Wiesner J, Arauz G, Bansal V, Esbona K, Capitini CM, Matkowskyj KA, Deming DA, Politi K, Abrams SI, Harismendy O, Asimakopoulos F. PMID: 35977482; PMCID: PMC9402878.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    5. Matrix proteoglycans in tumor inflammation and immunity. Am J Physiol Cell Physiol. 2022 09 01; 323(3):C678-C693. Deb G, Cicala A, Papadas A, Asimakopoulos F. PMID: 35876288; PMCID: PMC9448345.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    6. Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. Blood. 2021 01 07; 137(1):61-74. Wen Z, Rajagopalan A, Flietner ED, Yun G, Chesi M, Furumo Q, Burns RT, Papadas A, Ranheim EA, Pagenkopf AC, Morrow ZT, Finn R, Zhou Y, Li S, You X, Jensen J, Yu M, Cicala A, Menting J, Mitsiades CS, Callander NS, Bergsagel PL, Wang D, Asimakopoulos F, Zhang J. PMID: 32640012; PMCID: PMC7808014.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    7. Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity. J Histochem Cytochem. 2020 12; 68(12):871-885. Papadas A, Arauz G, Cicala A, Wiesner J, Asimakopoulos F. PMID: 32623942; PMCID: PMC7711242.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    8. Versican in the Tumor Microenvironment. Adv Exp Med Biol. 2020; 1272:55-72. Papadas A, Asimakopoulos F. PMID: 32845502.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    9. Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. Leuk Lymphoma. 2019 10; 60(10):2558-2562. Dhakal B, Pagenkopf A, Mushtaq MU, Cunningham AM, Flietner E, Morrow Z, Papadas A, Hope C, Leith C, Hematti P, Hari P, Callander NS, Asimakopoulos F. PMID: 30845856; PMCID: PMC7176050.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    10. TIGIT checkpoint inhibition for myeloma. Blood. 2018 10 18; 132(16):1629-1630. Asimakopoulos F. PMID: 30337318.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    11. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. J Immunother Cancer. 2018 07 03; 6(1):65. Mushtaq MU, Papadas A, Pagenkopf A, Flietner E, Morrow Z, Chaudhary SG, Asimakopoulos F. PMID: 29970158; PMCID: PMC6029413.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCells
    12. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Mar 01; 4(3):343-350. Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN. PMID: 29302684; PMCID: PMC5885822.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    13. Mechanisms of Resistance in Multiple Myeloma. Handb Exp Pharmacol. 2018; 249:251-288. Papadas A, Asimakopoulos F. PMID: 28315070.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    14. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma. J Biol Chem. 2018 02 16; 293(7):2452-2465. Huynh M, Pak C, Markovina S, Callander NS, Chng KS, Wuerzberger-Davis SM, Bakshi DD, Kink JA, Hematti P, Hope C, Asimakopoulos F, Rui L, Miyamoto S. PMID: 29279332; PMCID: PMC5818187.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    15. Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer. J Immunol. 2017 09 01; 199(5):1933-1941. Hope C, Emmerich PB, Papadas A, Pagenkopf A, Matkowskyj KA, Van De Hey DR, Payne SN, Clipson L, Callander NS, Hematti P, Miyamoto S, Johnson MG, Deming DA, Asimakopoulos F. PMID: 28754680; PMCID: PMC5568487.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    16. Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. J Leukoc Biol. 2017 08; 102(2):265-275. Asimakopoulos F, Hope C, Johnson MG, Pagenkopf A, Gromek K, Nagel B. PMID: 28254840; PMCID: PMC5505742.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    17. Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood. 2016 08 04; 128(5):680-5. Hope C, Foulcer S, Jagodinsky J, Chen SX, Jensen JL, Patel S, Leith C, Maroulakou I, Callander N, Miyamoto S, Hematti P, Apte SS, Asimakopoulos F. PMID: 27259980; PMCID: PMC4974200.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansAnimalsCells
    18. Deploying myeloid cells against myeloma. Oncoimmunology. 2016 Mar; 5(3):e1090076. Jensen JL, Hope C, Asimakopoulos F. PMID: 27141348; PMCID: PMC4839315.
      View in: PubMed   Mentions: 2     Fields:    
    19. Single-molecule analysis reveals widespread structural variation in multiple myeloma. Proc Natl Acad Sci U S A. 2015 Jun 23; 112(25):7689-94. Gupta A, Place M, Goldstein S, Sarkar D, Zhou S, Potamousis K, Kim J, Flanagan C, Li Y, Newton MA, Callander NS, Hematti P, Bresnick EH, Ma J, Asimakopoulos F, Schwartz DC. PMID: 26056298; PMCID: PMC4485118.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    20. MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells. Integr Biol (Camb). 2015 Jun; 7(6):643-54. Pak C, Callander NS, Young EW, Titz B, Kim K, Saha S, Chng K, Asimakopoulos F, Beebe DJ, Miyamoto S. PMID: 25998180; PMCID: PMC4476551.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    21. Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunol Res. 2015 Aug; 3(8):881-90. Jensen JL, Rakhmilevich A, Heninger E, Broman AT, Hope C, Phan F, Miyamoto S, Maroulakou I, Callander N, Hematti P, Chesi M, Bergsagel PL, Sondel P, Asimakopoulos F. PMID: 25941352; PMCID: PMC4527950.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    22. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol. 2014 Oct; 74(4):875-82. Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, Asimakopoulos F, Miyamoto S. PMID: 25168296; PMCID: PMC4175433.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    23. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood. 2014 May 22; 123(21):3305-15. Hope C, Ollar SJ, Heninger E, Hebron E, Jensen JL, Kim J, Maroulakou I, Miyamoto S, Leith C, Yang DT, Callander N, Hematti P, Chesi M, Bergsagel PL, Asimakopoulos F. PMID: 24723682; PMCID: PMC4046426.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    24. Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma. 2013 Oct; 54(10):2112-21. Asimakopoulos F, Kim J, Denu RA, Hope C, Jensen JL, Ollar SJ, Hebron E, Flanagan C, Callander N, Hematti P. PMID: 23432691; PMCID: PMC3686978.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    25. MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages. Br J Haematol. 2013 Mar; 160(6):779-84. Hebron E, Hope C, Kim J, Jensen JL, Flanagan C, Bhatia N, Maroulakou I, Mitsiades C, Miyamoto S, Callander N, Hematti P, Asimakopoulos F. PMID: 23252623; PMCID: PMC3594344.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    26. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol. 2012 Aug; 158(3):336-46. Kim J, Denu RA, Dollar BA, Escalante LE, Kuether JP, Callander NS, Asimakopoulos F, Hematti P. PMID: 22583117; PMCID: PMC3395762.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCells
    Fotis's Networks
    Concepts (143)
    Derived automatically from this person's publications.
    _
    Co-Authors (18)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _